<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02077712</url>
  </required_header>
  <id_info>
    <org_study_id>CCPMOH2010-China4</org_study_id>
    <nct_id>NCT02077712</nct_id>
  </id_info>
  <brief_title>Intranasal Dexmedetomidine Sedation for Ophthalmic Examinations in Children</brief_title>
  <acronym>DEX-EYE</acronym>
  <official_title>A Randomised Comparison of Two Intranasal Dexmedetomidine Doses for Ophthalmic Examination Following Failed Chloral Hydrate Sedation in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      2 ug/kg of intranasal dexmedetomidine could produce satisfactory sedation in more children
      for ophthalmic examinations than the sedative effect of 1ug/kg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dexmedetomidine is an a2-adrenergic receptor agonist that provides sedation without
      respiratory depression.Clinical trials have demonstrated that intranasal dexmedetomidine in a
      dose of 1ug/kg produces satisfactory sedation in between 53% and 57% of children at
      anaesthetic induction. There are also reports using higher doses of intranasal
      dexmedetomidine. The investigators compared the sedative effect of 1ug/kg intranasal
      dexmedetomidine with those of 2 ug/kg for ophthalmic examinations in children aged 2
      months-10 years and hypothesised that the higher dose would produce satisfactory sedation in
      more children at the time of anaesthetic induction.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of participants with successful rescue sedation</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numbers of participants with completement of ophthalmic examinations</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sniffs Drugs</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine 1 ug/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 ug/kg of intranasal dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 2 ug/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 ug/kg of intranasal dexmedetomidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal dexmedetomidine</intervention_name>
    <description>1 or 2 ug/kg of intranasal dexmedetomidine</description>
    <arm_group_label>Dexmedetomidine 1 ug/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 2 ug/kg</arm_group_label>
    <other_name>Ai Bei Ning</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Need sedation for ophthalmic examinations

          -  Children who had failed chloral hydrate sedation, i.e.there was no evidence of
             sedation 30 min following administration.

          -  With informed consent from parents

        Exclusion Criteria:

          -  Children with gastroesophageal reflux

          -  Children with nausea and vomiting

          -  Children with apnea in the past three months

          -  Children with recent pneumonia, exacerbation of asthma, bronchitis and upper
             respiratory tract infection

          -  Children with severe arrhythmias, heart failure and cardiac structural abnormalities

          -  Children with facial abnormalities, who is expected to be difficult with effective
             mask ventilation

          -  Children with severe neurological disease

          -  Children with moyamoya disease

          -  Children who is allergy to For dexmedetomidine or chloral hydrate

          -  Preterm children, weight &lt;2 kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haotian Lin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoliang Gan, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Weirong Chen</last_name>
    <role>Study Director</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yizhi Liu, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haotian Lin</last_name>
    <phone>862087330493</phone>
    <email>gddlht@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haotian Lin</last_name>
      <phone>862087330493</phone>
      <email>gddlht@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.gzzoc.com</url>
    <description>Homepage of Zhongshan Ophthalmic Center</description>
  </link>
  <reference>
    <citation>Ambi US, Joshi C, Ganeshnavar A, Adarsh E. Intranasal dexmedetomidine for paediatric sedation for diagnostic magnetic resonance imaging studies. Indian J Anaesth. 2012 Nov;56(6):587-8. doi: 10.4103/0019-5049.104588.</citation>
    <PMID>23325950</PMID>
  </reference>
  <reference>
    <citation>Ray T, Tobias JD. Dexmedetomidine for sedation during electroencephalographic analysis in children with autism, pervasive developmental disorders, and seizure disorders. J Clin Anesth. 2008 Aug;20(5):364-8. doi: 10.1016/j.jclinane.2008.03.004.</citation>
    <PMID>18761245</PMID>
  </reference>
  <results_reference>
    <citation>Li BL, Yuen VM, Song XR, Ye J, Ni J, Huang JX, Irwin MG. Intranasal dexmedetomidine following failed chloral hydrate sedation in children. Anaesthesia. 2014 Mar;69(3):240-4. doi: 10.1111/anae.12533. Epub 2014 Jan 21.</citation>
    <PMID>24447296</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2014</study_first_submitted>
  <study_first_submitted_qc>March 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Haotian Lin</investigator_full_name>
    <investigator_title>Ophthalmologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

